Abera is developing the next generation vaccines and immunotherapies based on our proprietary vaccine delivery platform.
Abera’s proprietary vaccine delivery platform – BERA, enables high-level multivalent presentation of recombinant antigens on bacterial Outer Membrane Vesicles (OMVs) for strong stimulation of the immune system.
Abera develops vaccine candidates based its technology – BERA. The main candidate is a universal pneumococcal vaccine candidate and the company explores applications in immunotherapy.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to create efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experiences into new, innovative vaccines.
Sammanfattning av delårsrapport Q3 2021. FINANSIELL ÖVERSIKT FÖRSTA TRE KVARTALEN 2021 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 769 (653) kSEK Resultatet
Proof-of-concept data for Abera Bioscience’s latest vaccine platform based on protein bodies have been published in the journal Vaccine. The article reports on the examination
Abera Bioscience AB initiates collaboration with an American university to accelerate the development of a vaccine candidate based on the company’s latest vaccine platform comprising
Abera is dedicated to the development of novel vaccines to save lives and increase health globally.
Get in contact with us via the contact form or email: info@aberabio.com
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.